Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 8, 2006

Biovitrum to Improve Manufacturing Process for Protein-based Allergy Candidate

  • Biovitrum will develop and manufature Resistentia Pharmaceuticals’ new protein-based allergy drug, RES 08, for use in Phase III trials, under an agreement between the companies.

    Biovitrum will expand on the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the high demands of a Phase III trial and manufacture sufficient amounts of the drug for the trial. The project will run for more than two years beginning in November.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »